Systematic Review
Copyright ©The Author(s) 2019.
World J Clin Cases. Jan 26, 2019; 7(2): 156-170
Published online Jan 26, 2019. doi: 10.12998/wjcc.v7.i2.156
Table 1 Nutritional interventions to improve sarcopenia in cirrhosis
Ref.Study participant’s characteristicsStudy designSample sizeInterventionDuration of interventionDiagnosis of sarcopeniaResults
Marchesini et al[29], 2003mean age: 59 yr; males/females: 13/59; BMI: NA; CTP score: 9; setting: EuropeRCT174Intervention: Nutritional supplementation with BCCA (leucine, isoleucine and valine); Control: Lactalbumin or maltodextrins1 yrAnthropometric and BIASignificant increase in triceps skinfold thickness and MA fat area
Okumara et al[30], 2006Age: NA; Gender: NA; mean BMI: 21; CTP score: 6; setting: JapanCase control47Regular diet and late evening snack (rice ball)1 wkAnthropometric measurement i.e., AMA, AC and AMCNo significant differences in BMI, AC, AMC or AMA; improvement in RQ value in intervention group
Nakaya et al[31], 2007Age: 67; males/females: 20/18; mean BMI: 22.9; CTP score: 7; setting: JapanRCT48LES with BCAA enriched mixture or ordinary food such as rice ball or bread3 moAnthropometric measurements such as MAC and triceps skin fold thicknessNo significant improvement in the anthropometric parameter in either group
Les et al[32], 2011mean age: 64.1 ± 10.4; males/females: 88/28; mean BMI: NA; CTP score: 8; Setting: BarcelonaRCT116Intervention: Standard diet + 0.7 g of protein/kg + supplement of 30 g of BCAA; Control group: Standard diet + 0.7 g of protein/kg + maltodextrin56 wkAnthropometricIncreased in MA circumference and hand grip in intervention group
Sorrentino et al[33], 2012mean age: 65; males/females: 81/39; mean BMI: NA; CTP score: 12; setting: ItalyRCT120Group A: parenteral nutritional support + balanced diet + LES; Group B: balanced diet + LES; Group C: low sodium or sodium free diet12 moAnthropometric measurements such as MAC and triceps skin fold thicknessNo significant differences in the anthropometric measures in three groups. Significantly improved in the morbidity and mortality in group A and B
Dupont et al[34], 2012mean age: 54.6 ± 9.6; males/females: 65/43; mean BMI: 26; CTP score: 10; setting: FranceRCT99Enteral nutrition vs a symptomatic support; i.e., 30–35 kcal/kg per day of a polymeric solution for a period of 3–4 wk, through a nasogastric feeding tube. for three oral nutritional supplements per day for 2 mo.3 moAnthropometric measurements such as MAC and triceps skin fold thicknessNo change in arm muscle circumference
Maharshi et al[35], 2016mean age: 42; males/females: 5/25; mean BMI: NA; CTP score: 8; setting: IndiaRCT120Nutritional therapy (30-35 kcal/kg/d, 1.0-1.5 g vegetable protein/kg/d vs no nutritional therapy6 moAnthropometric measurements such as MAC and triceps skin fold thicknessSignificant improvement in the MAC, hand grip and skeletal muscle mass
Ruiz-Margain et al[36], 2017mean age: 47.8-54.9; males/females: 13/59; mean BMI: 26; CTP score: 6; setting: MexicoRCT72Intervention: BCAA + High protein and high fiber diet; Control: Only high protein and high fiber diet6 moAnthropometric measurement: triceps skin fold thickness and MACIncrease in muscle and decrease in fat mass in intervention group
Kitajima et al[37], 2017mean age: 71.3 ± 7.9; males/females: 9/12; mean BMI: 23.9; CTP score: NA; setting: JapanLongitudinal study; (pre-post intervention)21Diet supplemented with BCAA 3 x daily after meals48 wkCT scan and BIAΔIMAC and ΔSAI significantly correlated with Δserum albumin level. BCAA supplementation prevented the progression of sarcopenia in cirrhosis
Ohara et al[38], 2018mean age: 67; males/females: 53/17; mean BMI: 24.6; CTP score: 7; setting: JapanMatched case control; Cases: 35; Control: 3570Cases: Received L carnitine; Control: no supplementation6 moCT images: Psoas muscle indexSignificant suppression in the loss of skeletal muscle in intervention group
Table 2 Exercise interventions to improve sarcopenia in cirrhosis
Ref.Study participants characteristicsStudy designPatients enrolledInterventionDuration of interventionDiagnosis of sarcopeniaResults
Zenith et al[39], 2014mean age: 57 years; males/females: 15/4; mean BMI: 28; CTP score: 6; setting: CanadaRCT ; Intervention = 9; Control = 1019Supervised exercise (cycle ergometer 3 d/wk). 5 min warm up on low level cycling, exercise initiated at 30 min per session and increased by 2.5 min per session until study completion8 wkQuadriceps muscle thickness measured by ultrasound and thigh circumferencePeak VO2 thigh thickness and circumference increased at end of intervention
Debette-Gratien et al[40], 2015Mean Age: 51 ± 12; males/females: 6/3; mean BMI: NA; CTP score: 7; setting: FranceQuasi experimental (pre-post intervention)13Personalized Adapted Physical Activity12 wkFunctional capacity and muscle strengthPost intervention significant increase in the mean exercise VO2 peak and the mean quadriceps isometric strength
Roman et al[41], 2016mean age: 63; males/females: 17/6; mean BMI: 31; CTP score: 6; setting: SpainRCT23Intervention: 1-h session 3 times/wk; Control: Sham intervention12 wkFunctional capacity by CPET, Anthropometry, DEXA and Timed up and GO studyIncrease in total effort time, ventilatory anaerobic threshold time and upper thigh circumference. Decrease in MA and mid-thigh skin fold thickness. DEXA showed decrease in fat body mass and increase in lean body mass, lean appendicular mass and lean leg mass. No changes in the control group
Macias-Rodriguez et al[42], 2016mean age: 52; males/females: 19/6; mean BMI: 27.5; CTP score: 6; setting: MexicoRCT25Intervention group: PEP (personalized exercise program) (cycloergometry/kinesiotherapy plus nutrition); control: only nutrition14 wkBIA and CPETSignificant improvement in ventilatory efficiency (VE/VCO2) and phase angle
Kruger et al[43], 2018mean age: 53-56; males/females: 23/17; mean BMI: 29; CTP score: 6; setting: CanadaRCT40Home exercise training i.e., moderate to high intensity cycling exercise, 3 d/wk vs usual care8 wkMeasurement of peak VO2; Aerobic endurance using 6-min walk test; Ultrasound to measure thigh muscle circumference and massSignificant increase in peak VO2, aerobic endurance, thigh circumference and insignificant improvement in thigh muscle thickness as measured by the average feather index
Table 3 Combined life style intervention (exercise and nutrition) to improve sarcopenia in cirrhosis
Ref.Study participants characteristicsStudy designSample sizeInterventionDuration of interventionDiagnosis of sarcopeniaResults
Roman et al[44], 2014mean age: 43-75; males/females: 12/5; mean BMI: 27; CTP score: 7; setting: SpainRCT17Intervention: moderate exercise + oral leucine; Control: Placebo12 wkExercise capacity (6-min walk and 2-min step tests), anthropometric measurementSignificant increase in exercise capacity. Increase in lower thigh circumference. No changes in control group
Nishida et al[45], 2017 (medium risk)mean age: 47.8-54.9; gender: 6 females; mean BMI: 24.3; CTP score: 6; setting: JapanQuasi experimental (pre-post intervention)6Homes based step exercise at AT (140 min/wk) and BCAA supplementation (12.45 g/d)12 moCT scan to assess fat deposition in liver and IMACSignificantly increased AT; No changes in TBW, liver/spleen ratio or IMAC
Hiraoka et al[46], 2017median age (IQR): 66 (62-70); males/females: 13/20; child A/B: 30/3; median BMI (IQR): 23.2 (20.8-25.1); setting: JapanQuasi experimental (pre-post intervention)33BCAA supplementation as LES and additional 2000 steps/d prescribed6 moBIA Leg and Hand gripMuscle volume, leg and handgrip strength increased after post intervention
Berzigotti et al[47], 2017mean age: 56 ± 8; gender: 31/29; mean BMI: 33; CTP score: < 8; setting: SpainQuasi experimental (pre-post intervention)60 included and 50 completed the studyLS interventions which include: Reduce calorie intake of 500-1000 kCal/d (protein intake 20%-25%, Carbs: 45%-50% and fat content < 35%); Supervised exercise-60 min session of moderate exercise.16 wkBIA and anthropometric measurementsDecrease in TBW, fat mass; Unchanged lean mass
Table 4 Trans jugular intrahepatic portosystemic shunt to improve sarcopenia in cirrhosis
Ref.Study participants characteristicsStudy designSample sizeInterventionFollow up, mean ± SDDiagnosis of sarcopeniaResults
Plauth et al[48], 2004mean age: 60; gender: 13/8; mean BMI: 22.3; decompensated; setting: GermanyQuasi experimental (pre-post intervention study)21TIPS12 moAnthropometry, BIA, REE by indirect calorimeter and TBPIncreased muscle mass; no change in REE and fat mass
Tsein et al[49], 2013mean age: 55.5; gender: 59/30; mean BMI: 29; CTP score: 9; setting: USACase control; Cases: 57; Controls: 3257TIPS13.5 ± 11.9 moUnenhanced CT axial scanTotal psoas and paraspinal muscle area increased significantly after TIPS; post TIPS visceral fat volume decreased significantly
Montomoli et al[50], 2010mean age: 47.8-54.9; gender: 14/7; mean BMI: 26.2; MELD: 18; setting: DenmarkQuasi experimental (pre-post intervention study)21TIPS52 wkAnthropometry: body composition parameters such as dry lean mass and fat massPatient with normal weight has increased in dry lean mass. No changes in the fat mass
Table 5 Testosterone to improve sarcopenia in cirrhosis
Ref.Study participants characteristicsStudy designSample sizeInterventionInterventionDiagnosis of sarcopeniaResults
Yurci et al[51], 2011mean age: 52.17; mean BMI: 27.17; CTP score: 7; setting: TurkeyQuasi experimental (pre-post intervention study)16Testosterone gel 50 mg/d in hypo gonadal men6 moAnthropometric measurement: Muscle strength and skin fold thicknessMuscle strength increased significantly 3 mo post intervention
Sinclair et al[52], 2016mean Age: 55; male 100%; mean BMI: 28.8; CTP score: 9; setting: AustraliaRCT101Intramuscular testosterone undecanoate in men with low testosterone12 moAPLM by DEXAAPLM and TBM were significant higher in testosterone-treated subjects. No change in mortality
Table 6 Summary of scoring results in terms of risk of bias (low, medium or high) of all studies included in the review
Ref.Question and risk of bias
Study designStudy participantsMeasurements of interventionMeasurements of outcomesConfounding factorsBlinding% follow-upInfo on non-participantsAnalysisSample sizeOverall quality rating: Risk of bias
Debette-Gratien et al[40], 2015+1+1-1+1-10-1+10-10 = medium risk
Berzigotti et al[47], 2017+1+1+1+1000+1+1-15 = low risk
Hiraoka et al[46], 2017+10+1+1-10+1+1+1-14 = low risk
Nishida et al[45], 2016+1-1-1+1-10-1+10-1-2 = medium risk
Montomoli et al[50], 2010+1-10+1-10-1+10-1-1 = medium risk
Ohara et al[38], 2018+1-10000+1-1+10+1 = medium risk
Okumura et al[30], 2006-1-1+1000+1+1+1-1+1 = medium risk
Plauth et al[48], 2004+1-10+1-100+1+1-1+1 = medium risk
Tsein et al[49], 2013+10-1+100-1-1+1-1-1 = medium risk
Yurci et al[51], 2011+1+1-10-100-1+1-1-1 = medium risk
Kitajima et al[37], 2017+1+10+100+1+1+1-15 = low risk
Table 7 Risk of bias in randomized controlled trials
Ref.Random sequence generation (selection bias)Allocation concealment (Selection bias)Blinding of participants and personnel’s (performance bias)Blinding of outcome assessment (detection bias)Incomplete outcome data (Attrition bias)Selective Reporting (Reporting bias)Other bias
Marchesini et al[29], 2003+----??
Nakaya et al[31], 2007+----??
Les et al[32], 2011++??-??
Sorrentino et al[33], 2012+?----?
Dupont et al[34], 2012+?--???
Maharshi et al[35], 2016++--+??
Ruiz-Margain et al[36], 2017+?--?-?
Zenith et al[39], 2014++---??
Roman et al[41], 2016++---??
Kruger et al[43], 2018++---??
Roman et al[44], 2014+?---??
Macias-Rodriguez et al[42], 2016++---??
Sinclair et al[52], 2016++??-??